Who
Paula Soteropoulos
Director
Company insider
Files Form 4 as: Director, Rallybio; Director, Dianthus Therapeutics; Director, uniQure; Chief Executive Officer, Akcea Therapeutics.
In numbers
- Trades disclosed
- 95
- Buys
- 0
- Sells
- 23
- Bought
- $0
- Sold
- $8.0M
- Companies
- 4
- Companies where not an officer
- 3
- First trade
- 27 Jan 2017
- Last trade
- 16 Oct 2026
- Last filed
- 20 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Oct 2026filed 20 Oct 2026 | RLYB RallybioBiotechnology | SEC FORM 4 Code M | $8,4783,562 at $2.38 | filing |
| 16 Oct 2026filed 20 Oct 2026 | RLYB Rallybiooption or derivative · Biotechnology | SEC FORM 4 Code M | —3,562 at $0.00 | filing |
| 21 May 2026filed 22 May 2026 | DNTH Dianthus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,090 at $0.00 | filing |
| 21 May 2026filed 22 May 2026 | DNTH Dianthus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,090 at $0.00 | filing |
| 8 May 2026filed 11 May 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Code M | $5,056599 at $8.44 | filing |
| 8 May 2026filed 11 May 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Sold | $51K599 at $85.47 | filing |
| 8 May 2026filed 11 May 2026 | DNTH Dianthus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —599 at $0.00 | filing |
| 8 May 2026filed 11 May 2026 | DNTH Dianthus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —599 at $0.00 | filing |
| 8 May 2026filed 11 May 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Code M | $5,056599 at $8.44 | filing |
| 8 May 2026filed 11 May 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Sold | $51K599 at $85.47 | filing |
| 31 Mar 2026filed 1 Apr 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Code M | $5,056599 at $8.44 | filing |
| 31 Mar 2026filed 1 Apr 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Sold | $48K599 at $80.11 | filing |
| 31 Mar 2026filed 1 Apr 2026 | DNTH Dianthus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —599 at $0.00 | filing |
| 31 Mar 2026filed 1 Apr 2026 | DNTH Dianthus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —599 at $0.00 | filing |
| 31 Mar 2026filed 1 Apr 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Code M | $5,056599 at $8.44 | filing |
| 31 Mar 2026filed 1 Apr 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Sold | $48K599 at $80.11 | filing |
| 24 Mar 2026filed 26 Mar 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Code M | $233K27,594 at $8.44 | filing |
| 24 Mar 2026filed 26 Mar 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Sold | $2.2M27,594 at $78.05 | filing |
| 24 Mar 2026filed 26 Mar 2026 | DNTH Dianthus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —27,594 at $0.00 | filing |
| 24 Mar 2026filed 26 Mar 2026 | DNTH Dianthus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —27,594 at $0.00 | filing |
News
Analyzing Connect Biopharma (NASDAQ:CNTB) & Dianthus Therapeutics (NASDAQ:DNTH)DNTH · tickerreport.com · 22 Oct 2026Dianthus Therapeutics Recognized Among Fortune's 2026 Best Workplaces In BioPharmaDNTH · manilatimes.net · 13 Oct 2026
0 headlines in the last 90 days name Paula Soteropoulos; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.